Skip to main content

Table 3 Laboratory variables in all patients and patients with PE and some cancer types

From: Preoperative coagulation biomarkers associate with survival and pulmonary embolism after surgical treatment of non-spinal skeletal metastases

Biomarker (normal range)

All patients mean/median (range), number

PE patients mean/median (range), number

Multiple myeloma mean/median (range), number

Breast cancer mean/median (range), number

Kidney cancer mean/median (range), number

Lung cancer mean/median (range), number

P-value

PT (70–130%)

85/84 (16–133), n = 96

87.4/87.0 (47–115), n = 10

83/87 (39–106), n = 11

92/91 (62–133), n = 25

77/78 (16–131), n = 23

88.5/93.0 (32.0–121.0), n = 13

ns

APTT (28–37 s)

33/32 (24–46), n = 89

31.4/30.5 (25–46), n = 10

29.9/29.0 (25–35), n = 11

30.1/29.0 (24–39), n = 25

35/35 (27–46), n = 19

34/32 (28–46), n = 19

Myeloma: 0.046 Breast ca: 0.001 Kidney ca: 0.033

Thrombin time (17–25 s)

18/16 (14–140), n = 86

17/16 (15–21), n = 11

29.3/16.5 (15–140), n = 10

17/16 (14–23), n = 25

16/16 (14–19), n = 18

16/16 (15–18), n = 11

ns

Fibrinogen (2–4 g/l)

5.5/5.5 (0.5–10.1), n = 87

6.1/6.2 (4–8), n = 10

4.6–5.0 (0.7–6.8), n = 11

4.8/4.4 (2.3–8.0), n = 25

6.4/6.5 (3.4–9.8), n = 18

5.8/5.8 (4.0–7.1), n = 11

Myeloma: 0.043 Breast ca: 0.013 Kidney ca: 0.025

Antithrombin (85–125%)

99/98 (39–270), n = 85

120/111 (77–270), n = 10

98/100 (86–116), n = 9

100.6/102.5 (66–140)

100/99 (81–121), n = 18

96/92 (79–124), n = 11

ns

D-dimer (< 0.5 mg/l)

2.7/2.3 (0.2–6.9), n = 88

2.9/3.0 (1–5), n = 11

2.4–2.1 (0.2–5.0), n = 11

2.9/2.3 (0.5–5.7), n = 25

2.0/2.1 (0.3–5.0), n = 18

3.0/2.5 (1.4–5.0), n = 11

ns

FVIII (60–160 IU/dl)

250/223 (61–544), n = 62

295/270 (195–457), n = 7

258/287 (86–366), n = 7

240/226 (107–544), n = 16

239/213 (159–425), n = 13

243/214 (178–374), n = 9

ns

Leuc (3.4–8.2 E9/l)

8.1/7.6 (1.1–22.2), n = 100

9.6/9.6 (5.7–14.9), n = 2

6.9/6.3 (3.1–12.4), n = 11

7.3/7.6 (3.0–12.9), n = 27

8.2/8.0 (3.1–15.1), n = 23

11.2/10.1 (5.8–18.2), n = 13

Lung ca: 0.000

Hgb (134–167 g/l)

113/113 (64–151), n = 100

116/118 (89–150), n = 12

106/101 (64–150), n = 11

120/123 (98–142), n = 27

109/105 (78–144), n = 23

114/113 (87–139), n = 13

Breast ca: 0.014

PLT 150–360 E9/l)

267/267 (46–636), n = 100

275/292 (80–499), n = 12

201/159 (80–402), n = 11

238.9/243.0 (46–414), n = 27

301/286 (123–636), n = 23

280/290 (169–414), n = 13

Myeloma: 0.022

Crea (60–100 umol/l)

86/68 (32–776), n = 99

84/78 (46–181), n = 12

120/85 (58–361), n = 11

61/61 (32–112), n = 27

127/89 (50–776), n = 23

72/61 (41–159), n = 13

Myeloma: 0.033 Breast ca: 0.003 Kidney ca: 0.000

  1. Hgb hemoglobin; PLT Platelet count; ns nonsignificant; ca cancer